Showing results (481-490 of 550) with videos related to
Sort By:
Pageof 55
JAMA|October 8, 2014
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trialRobert B Belshe, Sharon E Frey, Irene L Graham, et al.Vaccine|July 29, 2017
Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical TrialMark J Mulligan, Jack T Stapleton, Wendy A Keitel, et al.Journal of Medicinal Chemistry|July 14, 2021
Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with SchizophreniaHolly A Reichard, Hans H Schiffer, Holger Monenschein, et al.Vaccine|October 17, 2024
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adultsVarun K Phadke, Daniel J Gromer, Paulina A Rebolledo, et al.Iscience|January 12, 2024
mRNA COVID-19 vaccine elicits potent adaptive immune response without the acute inflammation of SARS-CoV-2 infectionEllie N Ivanova, Jasmine Shwetar, Joseph C Devlin, et al.Medrxiv : the Preprint Server for Health Sciences|April 28, 2021
mRNA COVID-19 vaccine elicits potent adaptive immune response without the persistent inflammation seen in SARS-CoV-2 infectionEllie N Ivanova, Jasmine Shwetar, Joseph C Devlin, et al.Annals of Clinical and Translational Neurology|September 27, 2022
Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapiesIlya Kister, Ryan Curtin, Jinglan Pei, et al.The Lancet. Infectious Diseases|June 18, 2026
Neutralising antibody responses to MPXV clades Ia, Ib, and IIb after infection or vaccination: a multicountry observational studyJameson Crandell, Raianna F Fantin, Leonardo Pereira de Araújo, et al.The Journal of Infectious Diseases|February 18, 1998
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection GroupB S Graham, M J McElrath, R I Connor, et al.The Journal of Pharmacology and Experimental Therapeutics|April 2, 2021
Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson DiseaseNicola L Brice, Hans H Schiffer, Holger Monenschein, et al.Pageof 55